Clinical trial
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
NCT07594925 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 1, 2026
- Completion date
- March 1, 2030
- Enrollment
- 130 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
rectal cancer